CompanyCRDFNasdaqSan Diego, CA

Cardiff Oncology

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor.

8-KSep 14Latest SEC filing, period to Sep 14

Aug 11Latest story

August 2026

Aug 11Quarterly updateCardiff Oncology

July 2026

Jul 16PartnershipCardiff Oncology